FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to nucleic acid encoding a chimeric antigen receptor (CAR) containing a domain binding MUC16 antigen, a transmembrane domain, and an intracellular signal domain, as well as to a vector and a cell containing it. A method for stimulation of proliferation and/or survival of constructed T-cells is also disclosed, providing for the use of the above-mentioned nucleic acid.
EFFECT: invention is effective for the treatment of cancer in a subject.
19 cl, 20 dwg, 11 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS TARGETING DLL3 | 2020 |
|
RU2822366C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
| COMPOSITIONS AND METHODS OF SELECTIVE PROTEIN DEGRADATION | 2018 |
|
RU2811700C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING VARIANT III OF EPIDERMAL GROWTH FACTOR RECEPTOR | 2017 |
|
RU2751662C2 |
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
